Select Page

With several promising DMTs and diagnostic biomarkers for AD approved or in clinical development, the biopharmaceutical industry needs to help health systems prepare for future adoption and maximum patient impact.

Recognizing that researchers and policymakers around the world have an incomplete understanding of the true burden of Alzheimer’s, Shift Health led a multipronged research effort to characterize what is known about the direct, indirect and intangible costs of AD—for patients, caregivers, health systems and society—and call attention to gaps that are leading to systematic underestimation of current and future impact. Our work resulted in a landmark publication on the costs of AD, informed the company’s integrated global AD access strategy, and supported evidence-based dialogue with decision-makers about the potential value of early detection and intervention.

We have since built on that foundational study by working with our clients to organize and serve on several panels at various international conferences, and we are developing new white papers to build awareness of the multifaceted burden of AD and the need to expand notions of ‘value’ when assessing the potential impact of new AD interventions.

We are consistently impressed with the outstanding ideas, strategy and vision that Shift Health provides.


DR. JEROME KIM   Director General, International Vaccine Institute